Skip to main content

Master of Public Health

Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors

AUTHORS

Schafer JM , Lehmann BD , Gonzalez-Ericsson PI , Marshall CB , Beeler JS , Redman LN , Jin H , Sanchez V , Stubbs MC , Scherle P , Johnson KN , Sheng Q , Roland JT , Bauer JA , Shyr Y , Chakravarthy B , Mobley BC , Hiebert SW , Balko JM , Sanders ME , Liu PCC , Pietenpol JA , . Science translational medicine. ; 12(534).

ABSTRACT

Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer that does not respond to endocrine therapy or human epidermal growth factor receptor 2 (HER2)-targeted therapies. Individuals with TNBC experience higher rates of relapse and shorter overall survival compared to patients with receptor-positive breast cancer subtypes. Preclinical discoveries are needed to identify, develop, and advance new drug targets to improve outcomes for patients with TNBC. Here, we report that MYCN, an oncogene typically overexpressed in tumors of the nervous system or with neuroendocrine features, is heterogeneously expressed within a substantial fraction of primary and recurrent TNBC and is expressed in an even higher fraction of TNBCs that do not display a pathological complete response after neoadjuvant chemotherapy. We performed high-throughput chemical screens on TNBC cell lines with varying amounts of MYCN expression and determined that cells with higher expression of MYCN were more sensitive to bromodomain and extraterminal motif (BET) inhibitors. Combined BET and MEK inhibition resulted in a synergistic decrease in viability, both in vitro and in vivo, using cell lines and patient-derived xenograft (PDX) models. Our preclinical data provide a rationale to advance a combination of BET and MEK inhibitors to clinical investigation for patients with advanced MYCN-expressing TNBC.

Tags: